Overview

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

Status:
Completed

Trial end date:
2020-04-16

Target enrollment:

Participant gender:

Summary

Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent patients with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD

Phase:

Phase 3

Details

Lead Sponsor:

H. Lundbeck A/S

Treatments:

Vortioxetine